纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | SLC7A11 |
Uniprot No | Q9UPY5 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-501aa |
氨基酸序列 | MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYILEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGITVVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAFSGRDSSITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLSNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIMSEKITRTLQIILEVVPEEDKL |
预测分子量 | 58.2 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"SLC7A11/xCT is a target of CRISPR-mediated gene editing for enhancing antioxidant capacity in mammalian cells"**
*作者:Li Y, et al.*
摘要:研究通过CRISPR技术编辑SLC7A11基因,重组蛋白表达显著增强细胞对氧化应激的抵抗能力,验证了其在调节谷胱甘肽合成中的关键作用。
2. **"Recombinant SLC7A11 protein suppresses ferroptosis by promoting cystine uptake in lung cancer cells"**
*作者:Wang L, et al.*
摘要:体外表达纯化的SLC7A11重组蛋白被证实可促进肺癌细胞胱氨酸摄取,抑制铁死亡,为靶向SLC7A11的癌症治疗提供实验依据。
3. **"Structural insights into the human SLC7A11 transporter by cryo-EM"**
*作者:Zhang X, et al.*
摘要:利用冷冻电镜解析SLC7A11重组蛋白的分子结构,揭示其胱氨酸/谷氨酸反向转运的机制及潜在药物结合位点。
4. **"High-throughput screening identifies SLC7A11 inhibitors as potential anticancer agents"**
*作者:Chen H, et al.*
摘要:通过重组SLC7A11蛋白建立药物筛选平台,发现新型抑制剂可阻断胱氨酸转运并诱导肿瘤细胞铁死亡,具有抗肿瘤应用前景。
SLC7A11. also known as xCT, is a key component of the cystine/glutamate antiporter system xc−, a heterodimeric transmembrane transporter composed of SLC7A11 (the light chain) and SLC3A2 (the heavy chain). This system mediates the cellular uptake of cystine in exchange for intracellular glutamate, playing a critical role in maintaining cellular redox homeostasis. Cystine is rapidly reduced to cysteine, a rate-limiting precursor for glutathione (GSH) synthesis, a major antioxidant that protects cells against oxidative stress. Dysregulation of SLC7A11 is implicated in various pathological conditions, including cancer, neurodegenerative diseases, and ferroptosis, a form of iron-dependent regulated cell death.
In cancer biology, SLC7A11 is frequently overexpressed in tumors, promoting cystine uptake and GSH synthesis to enhance antioxidant capacity and resistance to oxidative damage. Paradoxically, this dependency can create a metabolic vulnerability, as excessive cystine uptake may deplete intracellular glutamate pools, impairing nucleotide synthesis and sensitizing cells to ferroptosis under specific conditions. Consequently, SLC7A11 has emerged as a therapeutic target, with inhibitors being explored to induce ferroptosis in cancer cells.
Recombinant SLC7A11 protein is engineered for functional studies, enabling researchers to investigate its transport kinetics, structural features, and interactions with regulatory molecules. It is typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications and membrane localization. Studies using recombinant SLC7A11 have clarified its role in redox regulation, identified binding partners (e.g., p53. NRF2), and validated pharmacological modulators. Its applications extend to drug screening, biomarker development, and mechanistic studies linking cysteine metabolism to disease progression, offering insights for precision therapies targeting oxidative stress pathways.
×